“Health economic implications of irbesartan plus conventional antihypertensive medications versus conventional blood pressure control alone in patierns with type 2 diabetes, hypertension, and renal disease in Switzerland” (2006) Swiss Medical Weekly, 136(2122), pp. 346–346. doi:10.57187/smw.2006.11337.